A Rare but Morbid Occurrence: Development of Glioblastoma Multiforme During Tumor Necrosis Factor Inhibitor Therapy

Abstract

The use of biologic therapies continues to become more prevalent in the treatment of inflammatory bowel disease, particularly for more severe disease. Although generally safe and effective, specific biologic classes such as tumor necrosis factor inhibitor (anti-TNF) medications are known to increase the risk of certain cancers. Glioblastoma multiforme (GBM) is an aggressive brain tumor which tends to arise sporadically but may be associated with anti-TNF therapies. Here, we present a case of a 69-year-old male with Crohn’s disease who developed GBM while on adalimumab therapy. This case report highlights the potential rare association between GBM and anti-TNF therapy and further discusses the difficulty of managing active Crohn’s disease with concomitant GBM, specifically the difficulty encountered in managing a disease flare.

Anti-cancer and neuroprotective effects of conjugated graphene quantum dot in brain tumor-bearing rat model

“…and bregma-induced groups showed a significant (p<0.01) elevation in serum LDH level. While the lambda-induced group showed a higher significance (p < 0.001) rise in serum LDH level compared to normal control and other tumor-induced groups [68]. From figures 7D (b), it was observed that plain GQD, GQD-BSA, and GQD-Caspase 8 conjugations treated groups showed a significant (p < 0.01) reduction in serum LDH level.…”

“…Glutaminolysis-induced lactate secretion was strongly associated with angiogenesis, tumor migration, and growth [79]. The highest elevated serum LDH level was observed in the lambda-induced group compared to normal control and other induced groups [68]. Histopathological analysis of tumor-induced rat brain cortex and hippocampal regions showed tissue damage.…”